ACEI
|
Oral |
Dry cough |
Impaired degradation of bradykinin and substance P which mediated by ACE, causing enhanced cough reflex, accumulation of AA derivatives, nitric oxide production |
|
Sitagliptin
|
Oral |
Cough, rhinorrhea, dyspnea, wheeze |
May aggravate underlying allergic conditions |
|
Calcium channel blocker
|
Usually oral |
Cough with or without reflux symptoms |
May aggravate underlying reflux conditions |
|
Fentanyl
|
IV |
Cough, bronchoconstriction (usually in perioperative settings) |
May inhibit central sympathetic tone and increase vagal tone |
|
Latanoprost
|
Ophthalmic |
Dry cough |
Absorption of PGF2-α may enhance cough reflex in central nerve systems |
|
Miscellaneous:
|
Topiramate
|
Oral |
Dry cough |
Unknown |
Phenytoin
|
Oral, IV |
Nocturnal dry cough |
Unknown |
Methotrexate
|
Oral |
Dry cough |
Unknown |
Mycophenolate mofetil
|
Oral |
Dry cough |
Unknown |
Omeprazole
|
Oral |
Dry cough, worsened at night |
Unknown |